Robert Fishel Retires from OPKO Health, Inc.s Board of Directors
January 24, 2022 at 09:09 pm
Share
On January 21, 2022, Dr. Robert Fishel notified OPKO Health, Inc. (the 'Company'), that he was retiring from service on the Company's Board of Directors (the 'Board'), effective January 21, 2022. Dr. Fishel previously served as a director of the Company since April 2018. At the time of his resignation, Dr. Fishel served on the Compensation Committee and the Succession Committees and was the chair of the Independent Investment Committee of the Board.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.